Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Multicentre, Randomised, Double-blind, Placebo controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus

Next Previous
X
Search
Trial Profile

A Phase 2b, Multicentre, Randomised, Double-blind, Placebo controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cotadutide (Primary) ; Semaglutide
  • Indications Renal failure; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

    • Most Recent Events

    • 01 Dec 2024 Results published in the Kidney International
    • 06 Oct 2023 Primary endpoint (To assess the effects of cotadutide at different dose levels compared to placebo on UACR after 14 weeks) has been met, according to Results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
    • 06 Oct 2023 Results assessing the effect of cotadutide on both renal and glycaemic endpoints in patients with DKD presented at the 59th Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top